Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06889 (
Mol
)
630,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The concentration of calcium-binding protein
regucalcin
in the tissues of rats was estimated by enzyme-linked immunoadsorbent assay (ELISA) with rabbit-anti-
regucalcin
IgG. In male rats (5 weeks old),
regucalcin
was most pronounced in the liver. Liver regulcalcin concentration was about 0.1 microM, when it was calculated with
regucalcin
molecular weight of 28,800. The relatively higher level of
regucalcin
was also found in the kidney as compared with that of the skeletal muscle, duodenum, testis, lung, heart, spleen, cerebral cortex and hippocampus. Similarly in female rats,
regucalcin
was remarkable in the liver, and appeared only slightly in the kidney. Thus, the tissue distribution of
regucalcin
in rats was specific in the liver. The concentration of
regucalcin
in the liver was altered with increasing age of rats; liver
regucalcin
level linearly increased during 5 weeks old after birth of male rats, and then began to decrease gradually. The results coincided with the previous observation of Northern blot analyses by using liver
regucalcin
cDNA as a probe. The present finding clearly demonstrates that
regucalcin
is specifically synthesized in the liver of rats.
Mol
Cell Biochem 1993 May 12
PMID:Tissue concentration of calcium-binding protein regucalcin in rats by enzyme-linked immunoadsorbent assay. 835 Aug 65
The gene for a Ca(2+)-binding protein
regucalcin
was cloned from a rat genomic library which was constructed in lambda FIX II by screening with radiolabeled probe (complementary DNA of rat liver
regucalcin
). Positive clone had 19.9 kb insert of size and contained four exons of the gene coding for a rat
regucalcin
. These exons included the partial coding sequence (61.2% of open reading frame) and the entire 3'-untranslated region of the gene. The nucleotide sequence of exons completely agreed with that of a rat
regucalcin
cDNA clone. The sequence analysis of the clone showed that the identifier sequence and two simple repeated sequences exist in the intron of the gene. Moreover, chromosomal location of the rat
regucalcin
gene was determined by direct R-banding fluorescence in situ hybridization (FISH) method with the 19.9 kb clone containing four exons. The
regucalcin
gene was localized on rat chromosome Xq11.1-12 proximal end.
Mol
Cell Biochem 1995 Oct 18
PMID:Genomic cloning and chromosomal assignment of rat regucalcin gene. 856 61
The effect of hormonal signaling factors on (Ca(2+)-Mg2+)-ATPase activity in rat liver plasma membranes was investigated. The presence of inositol-glycan (10(-7)-10(-5) M), dibutyryl cAMP (10(-4) and 10(-3) M) or inositol 1,4,5-trisphosphate (IP3; 10(-6) and 10(-5) M) in the enzyme reaction mixture produced a significant increase in (Ca(2+)-Mg2+)-ATPase activity. These effects were completely inhibited by the presence of vanadate (10(-4) M), an inhibitor of the enzyme phosphorylation, and N-ethylmaleimide (5 x 10(-3) M), a SH group modifying reagent. Meanwhile,
regucalcin
, a Ca(2+)-binding protein isolated from rat liver cytosol, increased the enzyme activity by binding to the SH groups of (Ca(2+)-Mg2+)-ATPase in liver plasma membranes. The presence of
regucalcin
(0.25 microM) with an effective concentration completely inhibited the effect of inositol-glycan (10(-5) M) to increase (Ca(2+)-Mg2+)-ATPase activity, while the effect of dibutyryl cAMP (10(-3) M) or IP3 (10(-5) M) was not altered. The inositol-glycan effect was not modulated by the presence of dibutyryl cAMP or IP3. Now, the preincubation of the plasma membranes with
regucalcin
did not modify the effect of inositol-glycan on the enzyme activity, suggesting that
regucalcin
competes with inositol-glycan for the binding to the plasma membranes. The present results suggest that there may be a cross talk with
regucalcin
and hormonal signaling factors in the regulation of (Ca(2+)-Mg2+)-ATPase activity in liver plasma membranes.
Mol
Cell Biochem 1995 Oct 04
PMID:Stimulatory effect of hormonal signaling factors on (Ca(2+)-Mg2+)-ATPase activity in rat liver plasma membranes: cross talk with regucalcin. 858 7
The alteration of Ca(2+)-binding protein
regucalcin
mRNA expression in the kidney cortex of rats administered cisplatin and cephaloridine, which can induce kidney damage, was investigated. Cisplatin (0.25, 0.5 and 1.0 mg/100 g body weight) or cephaloridine (25, 50 and 100 mg/100 g) was intraperitoneally administered in rats, and 1, 2 and 3 days later they were sacrificed. The alteration in serum findings after the administration of cisplatin (1.0 mg/100 g) or cephaloridine (50 and 100 mg/100 g) demonstrated chemically induced kidney damage; blood urea nitrogen (BUN) concentration increased markedly and serum inorganic phosphorus or calcium concentration decreased significantly. Moreover, the administration of cisplatin (1.0 mg/100 g) or cephaloridine (100 mg/100 g) caused a remarkable increase of calcium content in the kidney cortex of rats, indicating kidney damage. The expression of
regucalcin
mRNA in the kidney cortex was markedly reduced by the administration of cisplatin or cephaloridine in rats, when the mRNA levels were analyzed by Northern blotting using rat liver
regucalcin
cDNA (0.9 kb). The mRNA decreases were seen with the used lowest dose of cisplatin or cephaloridine. The present study clearly demonstrates that the mRNA expression of Ca(2+)-binding protein
regucalcin
in the kidney cortex of rats is decreased by chemically induced kidney damage.
Mol
Cell Biochem 1995 Oct 04
PMID:Suppressed expression of calcium-binding protein regucalcin mRNA in the renal cortex of rats with chemically induced kidney damage. 858 14
The effect of various steroid hormones on the expression of calcium-binding protein
regucalcin
mRNA in the kidney cortex of rats was investigated. The change of
regucalcin
mRNA levels was analyzed by Northern blotting using rat liver
regucalcin
complementary DNA (0.9 kb of open-reading frame).
Regucalcin
mRNA was expressed in the kidney cortex but not the medulla. Rats received a single subcutaneous administration of steroid; the animals were sacrificed 60 min after the treatment of aldosterone (2.5, 5.0 and 10 micrograms/100 g body weight) or 6 h after the treatment of estrogen (17 beta-estradiol; 0.05, 0.1 and 0.2 mg/100 g), hydrocortisone (0.5, 1.0 and 3.0 mg/100 g) and dexamethasone (50, 100 and 150 micrograms/100 g).
Regucalcin
mRNA levels in the kidney cortex were clearly diminished by the administration of aldosterone or estrogen, while hydrocortisone administration had no effect. The administration of dexamethasone (100 micrograms/100 g) caused a remarkable increase of
regucalcin
mRNA levels in the kidney cortex. The dexamethasone-induced increase in
regucalcin
mRNA levels was completely blocked by the simultaneous administration of cycloheximide (150 micrograms/100 g), although the drug administration had no effect on the mRNA levels in control rats. Meanwhile, the dexamethasone administration did not cause an appreciable alteration of calcium content in the kidney cortex. The present study demonstrates that, of the various steroid hormones used, dexamethasone uniquely has a stimulatory effect on
regucalcin
mRNA expression in the kidney cortex of rats. The steroid effect may be mediated through a newly synthesized protein.
Mol
Cell Biochem 1996 Feb 23
PMID:Steroid hormonal regulation of calcium-binding protein regucalcin mRNA expression in the kidney cortex of rats. 870 Jan 55
Whether the gene expression of hepatic Ca(2+)-binding protein
regucalcin
is altered in hepatomas was investigated. The change in
regucalcin
mRNA levels was analyzed by Northern blotting using liver
regucalcin
complementary DNA (0.9 kb). Rat hepatoma was induced by continuous feeding of basal diet containing 0.06% 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB). After 35 weeks feeding, rats were sacrificed, and the non-tumorous and tumorous tissues of the livers were removed. In individual rats, the
regucalcin
mRNA levels in the tumorous tissues were generally decreased in comparison with that of the non-tumorous tissues of the chemical-fed rats, although the chemical administration might decrease the mRNA expression in normal rat liver, suggesting that the chemical administration causes a suppressive effect on the mRNA expression. When the genomic DNA extracted from the liver tumorous tissues was digested with restriction enzymes (EcoRI, BamHI and HindIII) and analyzed by Southern blotting, no rear-ranged band was found in the
regucalcin
gene from the hepatoma. Interestingly, in the transplantable Morris hepatoma cells, the
regucalcin
mRNA was markedly expressed, while the albumin mRNA was expressed only slightly. The present study demonstrates that
regucalcin
mRNA is clearly expressed in the transformed cells (Morris hepatoma cells).
Mol
Cell Biochem 1996 Feb 09
PMID:Expression of calcium-binding protein regucalcin mRNA in hepatoma cells. 871 43
The alteration of the plasma membrane (Ca(2+)-Mg2+)-ATPase activity in the liver of rats administered orally carbon tetrachloride (CCl4) solution was investigated. Rats received a single oral administration of CCl4 (10, 25 and 50%, 1.0 ml/100 g body weight), and 3 or 24 h later they were sacrificed. CCl4 administration caused a remarkable elevation of liver calcium content and a corresponding increase in liver plasma membrane (Ca(2+)-Mg2+)-ATPase activity, indicating that the increased Ca2+ pump activity is partly involved in calcium accumulation in liver cells. Moreover, the participation in
regucalcin
, which is an intracellular activating factor on the enzyme, was examined by using anti-
regucalcin
IgG. The plasma membrane (Ca(2+)-Mg2+)-ATPase activity increased by CCl4 administration was not entirely inhibited by the presence of anti-
regucalcin
IgG (1.0 and 2.5 ug/ml) in the enzyme reaction mixture. However, the effect of
regucalcin
(0.25-1.0 uM) to activate (Ca(2+)-Mg2+)-ATPase in the liver plasma membranes of normal rats was not revealed in the liver plasma membranes obtained from CCl4-administered rats. Also, the effect of
regucalcin
was not seen when the plasma membranes were washed with 1.0 mM EGTA, indicating that the disappearance of
regucalcin
effect is not dependent on calcium binding to the plasma membranes due to liver calcium accumulation. Now, the presence of dithiothreitol (5 mM) or heparin (20 ug/ml) caused a remarkable elevation of the plasma membrane (Ca(2+)-Mg2+)-ATPase activity in the liver obtained from CCl4-administered rats. Thus, the
regucalcin
effect differed from that of dithiothreitol or heparin. The present study suggests that the impairment of
regucalcin
effect on Ca2+ pump activity in liver plasma membranes is partly contribute to hepatic calcium accumulation induced by liver injury with CCl4 administration.
Mol
Cell Biochem 1996 May 10
PMID:Activatory effect of regucalcin on hepatic plasma membrane (Ca(2+)-Mg2+)-ATPase is impaired by liver injury with carbon tetrachloride administration in rats. 879 Dec 79
The 26S proteasome is a large multisubunit protease complex, the largest regulatory subunit of which is a component named p112. Molecular cloning of cDNA encoding human p112 revealed a polypeptide predicted to have 953 amino acid residues and a molecular mass of 105,865. The human p112 gene was mapped to the q37.1-q37.2 region of chromosome 2. Computer analysis showed that p112 has strong similarity to the Saccharomyces cerevisiae Sen3p, which has been listed in a gene bank as a factor affecting tRNA splicing endonuclease. The
SEN3
also was identified in a synthetic lethal screen with the nin1-1 mutant, a temperature-sensitive mutant of NIN1. NIN1 encodes p31, another regulatory subunit of the 26S proteasome, which is necessary for activation of Cdc28p kinase. Disruption of the
SEN3
did not affect cell viability, but led to temperature-sensitive growth. The human p112 cDNA suppressed the growth defect at high temperature in a
SEN3
disruptant, indicating that p112 is a functional homologue of the yeast Sen3p. Maintenance of
SEN3
disruptant cells at the restrictive temperature resulted in a variety of cellular dysfunctions, including defects in proteolysis mediated by the ubiquitin pathway, in the N-end rule system, in the stress response upon cadmium exposure, and in nuclear protein transportation. The functional abnormality induced by
SEN3
disruption differs considerably from various phenotypes shown by the nin1-1 mutation, suggesting that these two regulatory subunits of the 26S proteasome play distinct roles in the various processes mediated by the 26S proteasome.
Mol
Biol Cell 1996 Jun
PMID:CDNA cloning of p112, the largest regulatory subunit of the human 26s proteasome, and functional analysis of its yeast homologue, sen3p. 881 93
The effect of
regucalcin
, a Ca(2+)-binding protein isolated from rat liver cytosol, on deoxyribonucleic acid (DNA) synthesis in the nuclei of regenerating rat liver was investigated. At 1 day after partial hepatectomy, the liver weight was increased about 50% of that of sham-operated rats, and it reached to the same levels as sham operation at 3 days after hepatectomy. Nuclear DNA synthesis was markedly increased at 1 day after hepatectomy, and this increase was also seen at 3 days. Nuclear DNA synthesis was clearly enhanced in the presence of EGTA (0.4 mM) in the incubation mixture. The presence of Ca2+ (1.0-25 microM) caused a significant decrease in the nuclear DNA synthesis of normal rat liver.
Regucalcin
(0.25 and 0.5 microM) clearly inhibited the nuclear DNA synthesis of normal rat liver. This inhibition was also seen in the presence of Ca2+ (1.0 microM). Moreover, in the liver nuclei obtained at 1 day after partial hepatectomy, the presence of
regucalcin
(0.05-0.5 microM) caused a remarkable inhibition of nuclear DNA synthesis. This effect was also revealed in the presence of EGTA (0.4 mM). Thus, the inhibitory effect of
regucalcin
was remarkable in regenerating rat liver nuclei in comparison with that of normal rat liver. The present results demonstrate that
regucalcin
can suppress nuclear DNA synthesis in regenerating rat liver. We suppose that
regucalcin
may have a role in the regulation of nuclear DNA synthesis in liver cell proliferation.
Mol
Cell Biochem 1996 Sep 20
PMID:Calcium-binding protein regucalcin inhibits deoxyribonucleic acid synthesis in the nuclei of regenerating rat liver. 890 34
The alteration of (Ca(2+)-Mg2+)-ATPase activity in the plasma membranes of regenerating rat liver after a partial hepatectomy was investigated. Liver was surgically removed about two thirds of that of sham-operated rats. The reduced liver weight by partial hepatectomy was restored about 50% at 24 h after the surgery, and it was completely restored at 72 h. Regenerating liver significantly increased calcium content and plasma membrane (Ca(2+)-Mg2+)-ATPase activity between 12-48 h after hepatectomy. Those increases were maximum at 24 h after the surgery. The regenerating liver-induced increase in hepatic plasma membrane (Ca(2+)-Mg2+)-ATPase activity was completely abolished by the presence of anti-
regucalcin
IgG (1.0-4.0 micrograms/ml). The regenerating liver-induced increase in hepatic plasma membrane (Ca(2+)-Mg2+)-ATPase activity was clearly inhibited by N-ethylmaleimide (2.5 and 5.0 mM) addition into the enzyme reaction mixture. This NEM effect was also seen for the activatory effect with
regucalcin
(0.25 microM) addition on the enzyme activity in the plasma membranes from normal rat liver. The endogenous
regucalcin
may play a cell physiological role in the activation of the plasma membrane (Ca(2+)-Mg2+)-ATPase to maintain the intracellular calcium level in regenerating rat liver.
Mol
Cell Biochem 1996 Sep 20
PMID:Enhancement of plasma membrane (Ca(2+)-Mg2+)-ATPase activity in regenerating rat liver: involvement of endogenous activating protein regucalcin. 890 36
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>